Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Gains from Investment Securities: 2013-2024

Historic Gains from Investment Securities for ImmunityBio (IBRX) over the last 12 years, with Dec 2024 value amounting to -$20.0 million.

  • ImmunityBio's Gains from Investment Securities rose 52.42% to -$14.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$27.3 million, marking a year-over-year decrease of 138.35%. This contributed to the annual value of -$20.0 million for FY2024, which is 141.92% down from last year.
  • Latest data reveals that ImmunityBio reported Gains from Investment Securities of -$20.0 million as of FY2024, which was down 141.92% from $47.6 million recorded in FY2023.
  • In the past 5 years, ImmunityBio's Gains from Investment Securities ranged from a high of $47.6 million in FY2023 and a low of -$20.0 million during FY2024.
  • In the last 3 years, ImmunityBio's Gains from Investment Securities had a median value of $14.8 million in 2022 and averaged $14.1 million.
  • Per our database at Business Quant, ImmunityBio's Gains from Investment Securities skyrocketed by 863.62% in 2021 and then tumbled by 141.92% in 2024.
  • Yearly analysis of 5 years shows ImmunityBio's Gains from Investment Securities stood at $2.4 million in 2020, then soared by 863.62% to $23.1 million in 2021, then slumped by 35.85% to $14.8 million in 2022, then surged by 221.67% to $47.6 million in 2023, then plummeted by 141.92% to -$20.0 million in 2024.